Logo image of ENTX

ENTERA BIO LTD (ENTX) Stock Price, Quote, News and Overview

NASDAQ:ENTX - Nasdaq - IL0011429839 - Common Stock - Currency: USD

1.96  0 (0%)

ENTX Quote, Performance and Key Statistics

ENTERA BIO LTD

NASDAQ:ENTX (5/23/2025, 3:26:48 PM)

1.96

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2.79
52 Week Low1.41
Market Cap89.02M
Shares45.42M
Float34.76M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07/amc
IPO06-28 2018-06-28


ENTX short term performance overview.The bars show the price performance of ENTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

ENTX long term performance overview.The bars show the price performance of ENTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of ENTX is 1.96 USD. In the past month the price decreased by -16.6%. In the past year, price decreased by -15.52%.

ENTERA BIO LTD / ENTX Daily stock chart

ENTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.87 324.66B
AMGN AMGEN INC 13.09 146.15B
GILD GILEAD SCIENCES INC 13.88 133.76B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.92B
REGN REGENERON PHARMACEUTICALS 13.29 63.56B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.50B
ARGX ARGENX SE - ADR 99.72 35.74B
ONC BEIGENE LTD-ADR 5.98 25.93B
BNTX BIONTECH SE-ADR N/A 23.68B
NTRA NATERA INC N/A 20.81B
SMMT SUMMIT THERAPEUTICS INC N/A 19.21B
BIIB BIOGEN INC 7.96 18.44B

About ENTX

Company Profile

ENTX logo image Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.

Company Info

ENTERA BIO LTD

Hadassah / Jerusalem Bio, Park, 5th Floor

JERUSALEM 9112002 IL

CEO: Spiros Jamas

Employees: 19

ENTX Company Website

ENTX Investor Relations

Phone: 97225327151

ENTERA BIO LTD / ENTX FAQ

What is the stock price of ENTERA BIO LTD today?

The current stock price of ENTX is 1.96 USD.


What is the ticker symbol for ENTERA BIO LTD stock?

The exchange symbol of ENTERA BIO LTD is ENTX and it is listed on the Nasdaq exchange.


On which exchange is ENTX stock listed?

ENTX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ENTERA BIO LTD stock?

7 analysts have analysed ENTX and the average price target is 10.2 USD. This implies a price increase of 420.41% is expected in the next year compared to the current price of 1.96. Check the ENTERA BIO LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ENTERA BIO LTD worth?

ENTERA BIO LTD (ENTX) has a market capitalization of 89.02M USD. This makes ENTX a Micro Cap stock.


How many employees does ENTERA BIO LTD have?

ENTERA BIO LTD (ENTX) currently has 19 employees.


What are the support and resistance levels for ENTERA BIO LTD (ENTX) stock?

ENTERA BIO LTD (ENTX) has a support level at 1.9 and a resistance level at 2.07. Check the full technical report for a detailed analysis of ENTX support and resistance levels.


Is ENTERA BIO LTD (ENTX) expected to grow?

The Revenue of ENTERA BIO LTD (ENTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ENTX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ENTERA BIO LTD (ENTX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ENTERA BIO LTD (ENTX) stock pay dividends?

ENTX does not pay a dividend.


When does ENTERA BIO LTD (ENTX) report earnings?

ENTERA BIO LTD (ENTX) will report earnings on 2025-08-07, after the market close.


What is the Price/Earnings (PE) ratio of ENTERA BIO LTD (ENTX)?

ENTERA BIO LTD (ENTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).


What is the Short Interest ratio of ENTERA BIO LTD (ENTX) stock?

The outstanding short interest for ENTERA BIO LTD (ENTX) is 0.4% of its float. Check the ownership tab for more information on the ENTX short interest.


ENTX Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ENTX. When comparing the yearly performance of all stocks, ENTX is a bad performer in the overall market: 72.5% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ENTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ENTX. While ENTX has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ENTX Financial Highlights

Over the last trailing twelve months ENTX reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 50% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -101.61%
ROE -118.08%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%220%
Sales Q2Q%N/A
EPS 1Y (TTM)50%
Revenue 1Y (TTM)N/A

ENTX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to ENTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -124.4% and a revenue growth -100% for ENTX


Ownership
Inst Owners26.78%
Ins Owners2.69%
Short Float %0.4%
Short Ratio3.03
Analysts
Analysts82.86
Price Target10.2 (420.41%)
EPS Next Y-124.4%
Revenue Next Year-100%